Characterization of a chemokine receptor CCR5-negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype

Journal of Medical Virology

Volumn 80, Issue 2, 2008, Pages 192-200

  Binninger Schinzel, Dorothea ^a   Müller, Daniela ^a   Wolf, Timo ^b   Krause, Birgit ^a   Meye, Britta ^a   Winskowsky, Gudrun ^a   Raupp, Sylvia ^a   Norley, Stephen ^c   Brodt, Reinhard ^b   Werner, Albrecht ^d  

^a PAUL EHRLICH INSTITUT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d EUROPEAN COMMISSION   (Belgium)

Author keywords

Biological phenotyping; HIV coreceptor switch; HIV tropism; V3 region

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENTARY DNA; GAG PROTEIN; GENOMIC DNA; PLERIXAFOR; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CELL IMMORTALIZATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE SYSTEM; IMMUNOPHENOTYPING; INFECTION RESISTANCE; LYMPHOCYTE CLONE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL TRANSFORMATION, VIRAL; HIV INFECTIONS; HIV-1; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; RECEPTORS, CCR5; RECEPTORS, HIV;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 37549001030     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21064     Document Type: Article

References (40)

1. Berger EA, Murphy PM, Farber JM. 1999. Chemokine receptors as HIV coreceptors: Roles in viral entry, tropism, and disease. Ann Rev Immunol 17:657-700.
2. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, Kuruppu J, Yazdani J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. 2004. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: Implications for HIV pathogenesis. J Virol 78:1160-1168.
3. Briggs D, Tuttle D, Sleasman J, Goodenow M. 2000. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 14:2937-2939.
4. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, Gadkari DA. 2000. Absence of co-receptor switch with disease progression in human immunodeficiency virus infections in India. Virology 271:253-258.
5. Cheng-Mayer C, Quiroga M, Jung JW, Dina D, Levy JA. 1990. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol 64:4390-4398.
6. Chesebro B, Wehrly K, Nishio J, Perryman S. 1996. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol 70:9055-9059.
7. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected Individuals. J Exp Med 185:621-628.
8. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, ÓBrian SJ. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862.
9. Delobel P, Saundres-Sauné K, Casabat M, Pasquier C, Marchou B, Massip P, Izopet J. 2005. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiviral therapy. J Acquir Immune Defic Syndr 38:382-392.
10. Feinberg M, Moore JP. 2002. AIDS vaccine models: Challenging challenge viruses. Nat Med 8:207-210.
11. Fouchier RA, Groenink M, Koostra NA, Tersmette M, Huisman HG, Miedema F, Schiutemaker H. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66:3183-3187.
12. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. 2005. V3: HIV's Switch-Hitter. AIDS Res Hum Retrov 21:171-189.
13. Hoffmann NG, Seillier-Moiseiwitch F, Ahn J, Walker JM, Swanstrom R. 2002. Variability in the human immunodeficiency virus type 1 gpl20 ENV protein linked to phenotype-associated changes in the V3 loop. J Virol 76:3852-3864.
14. Holtkamp N, Otteken A, Findhammer S, Miller V, Kurth R, Werner A. 2000. Unexpected coreceptor usage of primary Human Immunodeficiency virus Type 1 isolates from viremic patients under highly active antiviral therapy. J Infect Dis 181:513-521.
15. Hung CS, Vander Heyden N, Ratner L. 1999. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol 73:8216-8226.
16. Jansson M, Backstrom E, Scarlatti G, Bjorndal A, Matsuda S, Rossi P, Albert J, Wigzell H. 2001. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res Hum Retroviruses 17:1405-1414.
17. Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, Goldsmith MA. 2003. In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 77:5846-5854.
18. Jensen M, Li FS, van't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77:13376-13388.
19. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA. 2003. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 77:7682-7688.
20. Kitchen CMR, Philpott S, Burger H, Weiser B, Anastos K, Suchard MA. 2004. Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral therapy: A Bayesian approach. J Virol 78:11296-11302.
21. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, Alizon M. 1998. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the Bicyclam AMD3100. Virology 72:6381-6388.
22. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, Stuhlmann ME, Koup RA, Landau NR. 1996. Homozygous defect in HIV coreceptor accounts for resistance of some multiply-exposed HIV-1 infection. Cell 86:367-377.
23. + T-cell clone (PMI): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 69:3712-3720.
24. Masciotra S, Owen SM, Rudolph D, Yang C, Wang B, Saksena N, Spira T, Dhawan S, Lal RB. 2002. Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS 16:1887-1898.
25. Meister S, Otto C, Papkalla A, Krumbiegel M, Pohlmann S, Kirchhoff F. 2001. Basic amino acid residues in the V3 loop of simian immunodeficiency virus envelope alter viral co-receptor tropism and infectivity but do not allow efficient utilization of CXCR4 as entry cofactor. Virology 284:287-296.
26. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K, Hinuma Y. 1981. Type C virus particles in a cord T cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 294:770-771.
27. Pastore C, Ramos A, Mosier DE. 2004. Intrinsic obstacles to human immunodeficiency virus type 1 co-receptor switching. J Virol 78: 7565-7574.
28. Penn ML, Grivel JC, Schramm B, Goldsmith MA, Margolis L. 1999. CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1 infected human lymphoid tissue. Proc Natl Aca Sci USA 96:663-668.
29. Pillai S, Good B, Richman D, Corbeil J. 2003. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 19:145-149.
30. Resch W, Hoffman N, Swanstrom R. 2001. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288:51-62.
31. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstege C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of a CCR-5 chemokine receptor gene. Nature 482:722-725.
32. Scarlatti G, Tresoldi E, Bjorndal A, Frederiksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyo EM, Lusso P. 1997. In vivo evolution of HIV coreceptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3:1259-1265.
33. Schols D. 1999. Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist. Verh K Acad Geneeskd Bel 61:551-564.
34. Seiki M, Hattori S, Hirayama Y, Yoshida M. 1983. Human adult T-cell leukaemia virus: Complete nucleotide sequence of the provirus genome integrated in leukaemia cell DNA. Proc Natl Acad Sci USA 80:3618-3622.
35. Shioda T, Levy JA, Cheng-Mayer C. 1992. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 89:9434-9438.
36. Stalmeijer EHB, van Rij RP, Boeser-Nunnink B, Visser JA, Naarding MA, Schols D, Schuitemaker H. 2004. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol 78:2722-2728.
37. Vodicka MA, Goh WC, Wu II, Rogel ME, Bartz SR, Schweickart VL, Raport CJ, Emerman M. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233:193-198.
38. Vodros D, Fenyo EM. 2005. Quantitative evaluation of HIV and SIV co-receptor use with GHOST (3) cell assay. Methods Mol Biol 304:333-342.
39. Xiao L, Owen SM, Goldman I, Lal AA, deJong JJ, Goudsmit J, Lal RB. 1998a. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 240:83-92.
40. Xiao L, Rudolph DL, Owen SM, Spira TJ, Lal RB. 1998b. Adaptation to promiscuous usage of CC and CXC-chemokine co-receptors in vivo correlates with HIV-1 disease progression. AIDS 12:F137-F143.